Title:Adenovirus-based Immunotherapy for Prostate Cancer
Volume: 8
Issue: 4
Author(s): Seema Dubey, Peter VanVeldhuizen and Dev Karan
Affiliation:
Keywords:
Prostate cancer vaccine, adenovirus vaccine, immunotherapy
Abstract: Prostate cancer is a significant health problem for men in the United States. While useful treatment modalities
are available, their therapeutic efficacies are limited and severe side effects remain a concern. Alternatively, immunotherapy
represents one of the most valuable treatments by inducing immune response targeting tumor cells. Sipuleucel-T is
the only FDA approved immunotherapeutic agent for the treatment of patients with metastatic castration-resistant prostate
cancer. Overall survival benefit with sipuleucel-T is modest, and the research field of cancer immunotherapy is continuously
expanding. Numerous methods designed to induce tumor-specific immunity are at various developmental stages in
clinical and preclinical studies. Among such modalities, the use of adenovirus vector (Ad) as an immunotherapy agent to
deliver tumor-associated antigens is an attractive and versatile vector system. In this review, we describe the potential use
of Ad-vector for prostate cancer immunotherapy.
